Roswell Park Comprehensive Cancer Center received a four-year $6.42 million U.S. Breakthrough Award through the Department of Defense’s Breast Cancer Research Program, and will embark on a three-part strategy for treating advanced cancers.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
